Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    November 2021
  1. VOGENSEN VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, et al
    Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0182921. doi: 10.1128/AAC.01829.
    PubMed     Abstract available


  2. YU JF, Xu JT, Yang SS, Gao MN, et al
    Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0146521. doi: 10.1128/AAC.01465.
    PubMed     Abstract available


    October 2021
  3. GANAPATHY US, Del Rio RG, Cacho-Izquierdo M, Ortega F, et al
    A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0151421. doi: 10.1128/AAC.01514.
    PubMed     Abstract available


  4. RADTKE KK, Ernest JP, Zhang N, Ammerman NC, et al
    Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling study.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705.
    PubMed     Abstract available


    September 2021
  5. ALMEIDA D, Converse PJ, Li SY, Upton AM, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0141221. doi: 10.1128/AAC.01412.
    PubMed     Abstract available


  6. ABDELWAHAB MT, Wasserman S, Brust JCM, Dheda K, et al
    Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0138121. doi: 10.1128/AAC.01381.
    PubMed     Abstract available


    August 2021
  7. SALAAM-DREYER Z, Streicher EM, Sirgel FA, Menardo F, et al
    Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0036421. doi: 10.1128/AAC.00364.
    PubMed     Abstract available


  8. VARGAS R JR, Freschi L, Spitaleri A, Tahseen S, et al
    The role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0116421. doi: 10.1128/AAC.01164.
    PubMed     Abstract available


  9. RAI D, Mehra S
    The mycobacterial efflux pump EfpA can induce high drug tolerance to many anti-tuberculosis drugs, including moxifloxacin, in Mycobacterium smegmatis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0026221. doi: 10.1128/AAC.00262.
    PubMed     Abstract available


  10. WAGH S, Rathi C, Lukka PB, Parmar K, et al
    Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0174420. doi: 10.1128/AAC.01744.
    PubMed     Abstract available


  11. GUO S, Wang B, Fu L, Chen X, et al
    In vitro and in vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 16:AAC0097421. doi: 10.1128/AAC.00974.
    PubMed     Abstract available


  12. ROBERTSON GT, Ramey ME, Massoudi LM, Carter CL, et al
    Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0058321. doi: 10.1128/AAC.00583.
    PubMed     Abstract available


  13. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    PubMed     Abstract available


  14. KIM S, Yamada WM, Duncanson B, Nole J, et al
    Building optimal 3-drug combination chemotherapy regimens to eradicate Mycobacterium tuberculosis in its slow growth acid phase.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0069321. doi: 10.1128/AAC.00693.
    PubMed     Abstract available


  15. CUMMING BM, Baig Z, Addicott KW, Chen D, et al
    Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0093221. doi: 10.1128/AAC.00932.
    PubMed     Abstract available


    July 2021
  16. CHIREHWA MT, Court R, de Kock M, Wiesner L, et al
    The effect of isoniazid intake on ethionamide pharmacokinetics and target attainment in multidrug-resistant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Jul 26:AAC0027821. doi: 10.1128/AAC.00278.
    PubMed     Abstract available


  17. YU W, Buhari Y, Wang S, Tian X, et al
    Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine and Linezolid in a Murine Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0070621. doi: 10.1128/AAC.00706.
    PubMed     Abstract available


  18. VAN SCHIE L, Borgers K, Michielsen G, Plets E, et al
    Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0065921. doi: 10.1128/AAC.00659.
    PubMed     Abstract available


  19. ERNEST JP, Sarathy J, Wang N, Kaya F, et al
    Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0050621. doi: 10.1128/AAC.00506.
    PubMed     Abstract available


  20. GEWITZ AD, Solans BP, Mac Kenzie WR, Heilig C, et al
    A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0179420. doi: 10.1128/AAC.01794.
    PubMed     Abstract available


  21. EGBELOWO O, Sarathy JP, Gausi K, Zimmerman MD, et al
    Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits.
    Antimicrob Agents Chemother. 2021 Jul 6:AAC0002421. doi: 10.1128/AAC.00024.
    PubMed     Abstract available


    June 2021
  22. WERNGREN J, Mansjo M, Glader M, Hoffner S, et al
    Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 28:AAC0072021. doi: 10.1128/AAC.00720.
    PubMed     Abstract available


  23. ZENG S, Zhang J, Sun M, Zhang X, et al
    Nitric oxide-dependent electron transport chain inhibition by the cytochrome bc1 inhibitor and pretomanid combination kills Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 21:AAC0095621. doi: 10.1128/AAC.00956.
    PubMed     Abstract available


  24. SHETYE GS, Choi KB, Kim CY, Franzblau SG, et al
    In Vitro Profiling of Anti-tubercular Compounds by Rapid, Efficient, and Non-Destructive Assays Using Auto-luminescent Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0028221. doi: 10.1128/AAC.00282.
    PubMed     Abstract available


  25. SHIBATA M, Masuda M, Sasahara K, Sasabe H, et al
    Prediction of Human Pharmacokinetic Profiles of the Anti-tuberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value Against Extrapulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0257120. doi: 10.1128/AAC.02571.
    PubMed     Abstract available


  26. ZAINABADI K, Walsh KF, Vilbrun SC, Mathurin LD, et al
    Characterization of differentially detectable Mycobacterium tuberculosis in the sputum of subjects with drug sensitive or drug resistant tuberculosis before and after two months of therapy.
    Antimicrob Agents Chemother. 2021 Jun 1:AAC0060821. doi: 10.1128/AAC.00608.
    PubMed     Abstract available


    May 2021
  27. JOHANSEN MD, Shalini, Kumar S, Raynaud C, et al
    Biological and biochemical evaluation of isatin-isoniazid hybrids as bactericidal candidates against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00011.
    PubMed     Abstract available


  28. MOK S, Roycroft E, Flanagan PR, Montgomery L, et al
    Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis isolates.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.02617.
    PubMed     Abstract available


  29. WASSERMAN S, Davis A, Stek C, Chirehwa M, et al
    Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00140.
    PubMed     Abstract available


    April 2021
  30. SONNENKALB L, Strohe G, Dreyer V, Andres S, et al
    Microevolution of Mycobacterium tuberculosis hetero-resistance subpopulations in a patient receiving 27 years of tuberculosis treatment in Germany.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02520.
    PubMed     Abstract available


  31. TASNEEN R, Mortensen DS, Converse PJ, Urbanowski ME, et al
    Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.00253.
    PubMed     Abstract available


  32. LEY SD, Pillay S, Streicher EM, van der Heijden YF, et al
    Melting the Eis: non-detection of kanamycin resistance markers by routine diagnostic tests and identification of new eis-promoter variants.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02502.
    PubMed     Abstract available


  33. ABDELWAHAB MT, Court R, Everitt D, Diacon AH, et al
    The effect of Clofazimine Concentration on QT prolongation in patients treated for tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.02687.
    PubMed     Abstract available


  34. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    PubMed     Abstract available


  35. LIN WH, Lee WT, Tsai HY, Jou R, et al
    Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes.
    Antimicrob Agents Chemother. 2021 Apr 12. pii: AAC.01573.
    PubMed     Abstract available


    March 2021
  36. ARDIZZONI E, Ariza E, Mulengwa D, Mpala Q, et al
    Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02263.
    PubMed     Abstract available


  37. MODLIN SJ, Marbach T, Werngren J, Mansjo M, et al
    Atypical Genetic Basis of Pyrazinamide Resistance in Mono-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.01916.
    PubMed     Abstract available


    February 2021
  38. OMOLLO C, Singh V, Kigondu E, Wasuna A, et al
    Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02554.
    PubMed     Abstract available


  39. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
    Deletion of Rv2571c confers resistance to arylamide compounds in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02334.
    PubMed     Abstract available


  40. VILCHEZE C, Jacobs WR Jr
    The promises and limitations of N-acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.01703.
    PubMed     Abstract available


  41. LUN S, Xiao S, Zhang W, Wang S, et al
    Therapeutic potential of coumestan Pks13 inhibitors for tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02190.
    PubMed     Abstract available


  42. PIETERMAN ED, van den Berg S, van der Meijden A, Svensson EM, et al
    Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02255.
    PubMed     Abstract available


  43. XU J, Converse PJ, Upton AM, Mdluli K, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02418.
    PubMed     Abstract available


    January 2021
  44. HO VQT, Verboom T, Rong MK, Habjan E, et al
    Heterologous expression of ethA and katG in Mycobacterium marinum enables the rapid identification of new prodrugs active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jan 25. pii: AAC.01445.
    PubMed     Abstract available


  45. DRUSANO GL, Kim S, Almoslem M, Schmidt S, et al
    The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available


  46. KHAN MZ, Nandicoori VK
    Deletion of PknG abates reactivation of latent Mycobacterium tuberculosis in mice.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02095.
    PubMed     Abstract available


  47. DRUSANO GL, Rogers S, Brown D, Peloquin CA, et al
    Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02533.
    PubMed     Abstract available


  48. ZHU H, Fu L, Wang B, Chen X, et al
    Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis, in different administration intervals in mouse tuberculosis models.
    Antimicrob Agents Chemother. 2021 Jan 11. pii: AAC.02164.
    PubMed     Abstract available


    December 2020
  49. VALAFAR SJ
    A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02091.
    PubMed     Abstract available


  50. LIN SY, Feng JY, Lee CY, Lin YC, et al
    Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02184.
    PubMed     Abstract available


    November 2020
  51. VIJAY S, Nhung HN, Bao NLH, Thu DDA, et al
    Most-probable number based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01439.
    PubMed     Abstract available


  52. IGNATIUS EH, Abdelwahab MT, Hendricks B, Gupte N, et al
    Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2020 Nov 23. pii: AAC.01196.
    PubMed     Abstract available


  53. PANJASAWATWONG N, Wattanakul T, Hoglund RM, Bang ND, et al
    Population pharmacokinetic properties of anti-tuberculosis drugs in Vietnamese children with tuberculous meningitis.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00487.
    PubMed     Abstract available


  54. GRZEGORZEWICZ AE, Lelievre J, Esquivias J, Angala B, et al
    Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
    Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01914.
    PubMed     Abstract available


    October 2020
  55. ARUN KB, Madhavan A, Abraham B, Balaji M, et al
    Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.00456.
    PubMed     Abstract available


  56. WILLBY M, Chopra P, Lemmer D, Klein K, et al
    Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
    PubMed     Abstract available


  57. MALLIKAARJUN S, Chapagain ML, Sasaki T, Hariguchi N, et al
    Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Pulmonary Multidrug-Resistant Tuberculosis Patients.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01207.
    PubMed     Abstract available


  58. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    PubMed     Abstract available


  59. RIFAT D, Li SY, Ioerger T, Shah K, et al
    Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01948.
    PubMed     Abstract available


  60. SATHKUMARA HD, Hansen K, Miranda-Hernandez S, Govan B, et al
    Disparate effects of metformin on Mycobacterium tuberculosis infection in diabetic and non-diabetic mice.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.01422.
    PubMed     Abstract available


  61. VAN DER WALT ML, Shean K, Becker P, Keddy KH, et al
    Treatment outcomes and adverse drug effects of ethambutol, cycloserine and terizidone for treatment of multi-drug resistant tuberculosis in South Africa.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00744.
    PubMed     Abstract available


    September 2020
  62. DRUSANO GL, Duncanson B, Scanga CA, Kim S, et al
    Developing new drugs for the therapy of Mycobacterium tuberculosis: What information do we get from pre-clinical animal models?
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01376.
    PubMed     Abstract available


  63. LI M, Nyantakyi SA, Go ML, Dick T, et al
    Resistance against membrane-inserting MmpL3 inhibitor through upregulation of MmpL5 in M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Sep 21. pii: AAC.01100.
    PubMed     Abstract available


    August 2020
  64. REICHMUTH ML, Homke R, Zurcher K, Sander P, et al
    Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naive Patients.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00513.
    PubMed     Abstract available


  65. CHIREHWA MT, Court R, De Kock M, Wiesner L, et al
    Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone.
    Antimicrob Agents Chemother. 2020 Aug 17. pii: AAC.01381.
    PubMed     Abstract available


  66. ALGHAMDI WA, Al-Shaer MH, An G, Alsultan A, et al
    Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimens Simulation and Target Attainment Analysis.
    Antimicrob Agents Chemother. 2020 Aug 10. pii: AAC.01174.
    PubMed     Abstract available


    July 2020
  67. LOISEAU C, Brites D, Reinhard M, Zurcher K, et al
    HIV coinfection is associated with low fitness rpoB variants in rifampicin-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 27. pii: AAC.00782.
    PubMed     Abstract available


  68. MARIOTTI S, Teloni R, de Turris V, Pardini M, et al
    Amphotericin B inhibits Mycobacterium tuberculosis infection of human alveolar type II epithelial A549 cells.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01164.
    PubMed     Abstract available


  69. AL-SHAER MH, Martson AG, Alghamdi WA, Alsultan A, et al
    Ethionamide population pharmacokinetic model and target attainment in multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00713.
    PubMed     Abstract available


  70. VILCHEZE C, Saranathan R, Weinrick B, Jacobs WR Jr, et al
    Characterization of large deletion mutants of Mycobacterium tuberculosis selected for isoniazid resistance.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00792.
    PubMed     Abstract available


    June 2020
  71. SAFI H, Lingaraju S, Ma S, Husain S, et al
    Rapidly-correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small Colony Variant Morphology.
    Antimicrob Agents Chemother. 2020 Jun 22. pii: AAC.00213.
    PubMed     Abstract available


  72. COHEN KA, Stott KE, Munsamy V, Manson AL, et al
    Evidence for expanding the role of streptomycin in the management of drug-resistant M. tuberculosis.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00860.
    PubMed     Abstract available


    May 2020
  73. LI Y, Dong W, Lan T, Fan J, et al
    Distribution of linezolid in tuberculosis lesions in patients with spinal multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00450.
    PubMed     Abstract available


  74. KIM HY, Srivastava S, Kumar Ak H, Marais BJ, et al
    Optimal dose or optimal exposure? Consideration for linezolid in tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00287.
    PubMed     Abstract available


  75. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00709.
    PubMed     Abstract available


    April 2020
  76. PIETERMAN ED, Sarink MJ, Sala C, Cole ST, et al
    Advanced quantification methods to improve the 18b dormancy model for assessing the activity of tuberculosis drugs in vitro.
    Antimicrob Agents Chemother. 2020 Apr 27. pii: AAC.00280.
    PubMed     Abstract available


  77. FARAJ A, Svensson RJ, Diacon AH, Simonsson USH, et al
    Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  78. HAYASHI M, Nishiyama A, Kitamoto R, Tateishi Y, et al
    Adduct Formation of Delamanid with NAD in Mycobacteria.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  79. NARMANDAKH E, Tumenbayar O, Borolzoi T, Erkhembayar B, et al
    Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.
    Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00537.
    PubMed     Abstract available


    March 2020
  80. HARIGUCHI N, Chen X, Hayashi Y, Kawano Y, et al
    OPC-167832, a novel carbostyril derivative with potent anti-tuberculosis activity as a DprE1 inhibitor.
    Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02020.
    PubMed     Abstract available


  81. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  82. ENKIRCH T, Werngren J, Groenheit R, Alm E, et al
    Systematic review of whole genome sequencing data to predict phenotypic drug resistance and susceptibility in Swedish Mycobacterium tuberculosis isolates 2016-2018.
    Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02550.
    PubMed     Abstract available


    February 2020
  83. RABIE H, Tikiso T, Lee J, Fairlie L, et al
    Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
    PubMed     Abstract available


  84. WALSH KF, McAulay K, Lee MH, Vilbrun SC, et al
    Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01956.
    PubMed     Abstract available


  85. GENGENBACHER M, Zimmerman MD, Sarathy JP, Kaya F, et al
    Tissue distribution of doxycycline in animal models of tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02479.
    PubMed     Abstract available


    January 2020
  86. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    Correction for Kempker et al., "A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment".
    Antimicrob Agents Chemother. 2020;64.
    PubMed    


  87. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02012.
    PubMed     Abstract available


  88. REINGEWERTZ TH, Meyer T, McIntosh F, Sullivan J, et al
    Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
    Antimicrob Agents Chemother. 2020;64.
    PubMed     Abstract available


  89. MTHIYANE T, Millard J, Adamson J, Balakrishna Y, et al
    N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376.
    PubMed     Abstract available


  90. WASSERMAN S, Huo S, Ky K, Malig YN, et al
    CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.
    Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145.
    PubMed     Abstract available


  91. ZHANG N, Strydom N, Tyagi S, Soni H, et al
    Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01727.
    PubMed     Abstract available


  92. JING W, Zong Z, Tang B, Wang J, et al
    Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01736.
    PubMed     Abstract available


    December 2019
  93. BJUGARD NYBERG H, Draper HR, Garcia-Prats AJ, Thee S, et al
    Population pharmacokinetics and dosing of ethionamide in children with tuberculosis.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01984.
    PubMed     Abstract available


  94. ELINGS W, Gaur A, Blok AJ, Timmer M, et al
    beta-Lactamase of Mycobacterium tuberculosis shows dynamics in the active site that increase upon inhibitor binding.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.02025.
    PubMed     Abstract available


  95. ABDELWAHAB MT, Leisegang R, Dooley KE, Mathad JS, et al
    Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01978.
    PubMed     Abstract available


    November 2019
  96. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01583.
    PubMed     Abstract available


    October 2019
  97. DONNELLAN S, Aljayyoussi G, Moyo E, Ardrey A, et al
    Intracellular pharmacodynamic modelling (PDi) is predictive of the clinical activity of fluoroquinolones against Tuberculosis.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.00989.
    PubMed     Abstract available


  98. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.
    Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215.
    PubMed     Abstract available


    September 2019
  99. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.00732.
    PubMed     Abstract available


    August 2019
  100. SALINGER DH, Subramoney V, Everitt D, Nedelman JR, et al
    Population Pharmacokinetics of Pretomanid.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00907.
    PubMed     Abstract available


  101. TUCKER EW, Pieterse L, Zimmerman MD, Udwadia ZF, et al
    Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
    Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.00913.
    PubMed     Abstract available


    July 2019
  102. ENIMIL A, Antwi S, Yang H, Dompreh A, et al
    Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old.
    Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00839.
    PubMed     Abstract available


    May 2019
  103. MALIK AA, Brooks MB, Siddiqui S, Fuad J, et al
    Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available


  104. GHIMIRE S, Maharjan B, Jongedijk EM, Kosterink JGW, et al
    Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available


    March 2019
  105. ISMAIL N, Peters RPH, Ismail NA, Omar SV, et al
    Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available


  106. MUSTAZZOLU A, Venturelli L, Dinarelli S, Brown K, et al
    A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available


    January 2019
  107. FRANCIS J, Zvada SP, Denti P, Hatherill M, et al
    Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01964.
    PubMed     Abstract available


  108. RICHARD M, Gutierrez AV, Viljoen A, Rodriguez-Rincon D, et al
    Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2018;63.
    PubMed     Abstract available


    November 2018
  109. KWARA A, Yang H, Antwi S, Enimil A, et al
    Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.
    Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657.
    PubMed     Abstract available


    September 2018
  110. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
    A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
    Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
    PubMed     Abstract available


    May 2018
  111. YEW WW, Chang KC, Chan DP
    Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: